Literature DB >> 21880559

Knock-down of SOX11 induces autotaxin-dependent increase in proliferation in vitro and more aggressive tumors in vivo.

Paolo Conrotto1, Ulrika Andréasson, Venera Kuci, Carl A K Borrebaeck, Sara Ek.   

Abstract

The transcription factor SOX11 is a novel diagnostic marker for mantle cell lymphoma (MCL), distinguishing this aggressive tumor from potential simulators. Recent data also show that the level of SOX11 correlates to in vitro growth properties in MCL, as well as the clinical progression. We have previously shown that MCL-associated pathways, such as Rb-E2F, are dysregulated leading to decreased proliferation upon overexpression of SOX11, emphasizing the impact of SOX11 on MCL-specific gene expression and growth control. However, it remains to be determined which growth regulatory pathways that are induced upon SOX11 knock-down, leading to an increased cellular growth. Consequently, we established a model cell line with constitutive down-regulation of SOX11. The highly proliferative features of this cell line were investigated by gene expression analysis, proliferation assay, cell cycle distribution and potential to induce tumors in NOD-SCID mice. Our in vitro studies demonstrated a SOX11-dependent regulation of MCL-specific gene expression. In addition, we identified autotaxin (ATX) to be regulated by SOX11. Our results clearly showed a correlation between SOX11 level and cellular growth rate, which was dependent on ATX, as well as a direct relation between the level of SOX11 in tumorigenic cells and the growth rate of these tumors in NOD-SCID mice.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880559      PMCID: PMC5528322          DOI: 10.1016/j.molonc.2011.08.001

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  41 in total

Review 1.  Bioactions and synthesis of a novel lipid mediator, cyclic phosphatidic acid.

Authors:  T Kobayashi; K Murakami-Murofushi
Journal:  World Rev Nutr Diet       Date:  2001       Impact factor: 0.575

2.  Dendritic cell-based therapy for mantle cell lymphoma.

Authors:  Corey M Munger; Julie M Vose; Shantaram S Joshi
Journal:  Int J Oncol       Date:  2006-06       Impact factor: 5.650

3.  Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma.

Authors:  Catherine A Tucker; Gwyn Bebb; Richard J Klasa; Mukesh Chhanabhai; Valia Lestou; Douglas E Horsman; Randy D Gascoyne; Adrian Wiestner; Dana Masin; Marcel Bally; Michael E Williams
Journal:  Leuk Res       Date:  2005-09-23       Impact factor: 3.156

Review 4.  Therapeutic potential of autotaxin/lysophospholipase d inhibitors.

Authors:  Lorenzo Federico; Zehra Pamuklar; Susan S Smyth; Andrew J Morris
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

5.  Mantle cell lymphoma with central nervous system involvement: frequency and clinical features.

Authors:  Saar Gill; Kirsten E Herbert; H Miles Prince; Max M Wolf; Andrew Wirth; Gail Ryan; Dennis A Carney; David S Ritchie; John M Davies; John F Seymour
Journal:  Br J Haematol       Date:  2009-08-19       Impact factor: 6.998

6.  Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma.

Authors:  Akiko Masuda; Kazuhiro Nakamura; Koji Izutsu; Koji Igarashi; Ryunosuke Ohkawa; Masahiro Jona; Katsumi Higashi; Hiromitsu Yokota; Shinichi Okudaira; Tatsuya Kishimoto; Takuro Watanabe; Yukako Koike; Hitoshi Ikeda; Yasushi Kozai; Mineo Kurokawa; Junken Aoki; Yutaka Yatomi
Journal:  Br J Haematol       Date:  2008-08-15       Impact factor: 6.998

7.  Cooperative function of POU proteins and SOX proteins in glial cells.

Authors:  K Kuhlbrodt; B Herbarth; E Sock; J Enderich; I Hermans-Borgmeyer; M Wegner
Journal:  J Biol Chem       Date:  1998-06-26       Impact factor: 5.157

8.  The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival.

Authors:  Xiao Wang; A Charlotta Asplund; Anna Porwit; Jenny Flygare; C I Edvard Smith; Birger Christensson; Birgitta Sander
Journal:  Br J Haematol       Date:  2008-08-20       Impact factor: 6.998

9.  S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool.

Authors:  Gilles Ferry; Natacha Moulharat; Jean-Philippe Pradère; Patrice Desos; Anne Try; Annie Genton; Adeline Giganti; Monique Beucher-Gaudin; Michel Lonchampt; Marc Bertrand; Jean-Sébastien Saulnier-Blache; Gordon C Tucker; Alex Cordi; Jean A Boutin
Journal:  J Pharmacol Exp Ther       Date:  2008-08-28       Impact factor: 4.030

10.  Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells.

Authors:  Sara Ek; Carl-Magnus Högerkorp; Michael Dictor; Mats Ehinger; Carl A K Borrebaeck
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

View more
  13 in total

1.  Knock-down of SOX11 induces autotaxin-dependent increase in proliferation in vitro and more aggressive tumors in vivo.

Authors:  Paolo Conrotto; Ulrika Andréasson; Venera Kuci; Carl A K Borrebaeck; Sara Ek
Journal:  Mol Oncol       Date:  2011-08-22       Impact factor: 6.603

2.  Impact of Sox11 over-expression in Ba/F3 cells.

Authors:  Martin Lord; Gustav Arvidsson; Agata M Wasik; Birger Christensson; Anthony P Wright; Alf Grandien; Birgitta Sander
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941

Review 3.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

4.  Aberrant SOX11 promoter methylation is associated with poor prognosis in gastric cancer.

Authors:  Xiaoyang Xu; Xiaojing Chang; Zhenhua Li; Jiang Wang; Peng Deng; Xinjiang Zhu; Jian Liu; Chundong Zhang; Shuchen Chen; Dongqiu Dai
Journal:  Cell Oncol (Dordr)       Date:  2015-03-24       Impact factor: 6.730

5.  Expanded clinical and experimental use of SOX11 - using a monoclonal antibody.

Authors:  Lena Nordström; Ulrika Andréasson; Mats Jerkeman; Michael Dictor; Carl Borrebaeck; Sara Ek
Journal:  BMC Cancer       Date:  2012-06-27       Impact factor: 4.430

6.  The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.

Authors:  Sandra Sernbo; Elin Gustavsson; Donal J Brennan; William M Gallagher; Elton Rexhepaj; Frida Rydnert; Karin Jirström; Carl Ak Borrebaeck; Sara Ek
Journal:  BMC Cancer       Date:  2011-09-24       Impact factor: 4.430

7.  A unique combination of male germ cell miRNAs coordinates gonocyte differentiation.

Authors:  Skye C McIver; Simone J Stanger; Danielle M Santarelli; Shaun D Roman; Brett Nixon; Eileen A McLaughlin
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

8.  Nuclear T-STAR protein expression correlates with HER2 status, hormone receptor negativity and prolonged recurrence free survival in primary breast cancer and decreased cancer cell growth in vitro.

Authors:  Sandra Sernbo; Carl A K Borrebaeck; Mathias Uhlén; Karin Jirström; Sara Ek
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

9.  Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function.

Authors:  January M Watters; Gabriela Wright; Matthew A Smith; Bijal Shah; Kenneth L Wright
Journal:  Biochem Biophys Res Commun       Date:  2020-11-13       Impact factor: 3.575

10.  Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival.

Authors:  P Korkolopoulou; G Levidou; E A El-Habr; C Adamopoulos; P Fragkou; E Boviatsis; M S Themistocleous; K Petraki; G Vrettakos; M Sakalidou; V Samaras; A Zisakis; A Saetta; I Chatziandreou; E Patsouris; C Piperi
Journal:  Br J Cancer       Date:  2013-04-25       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.